High-risk nonmuscle invasive bladder cancer

Anna Orsola; Joan Palou; Eduardo Solsona

doi:10.1016/j.hoc.2014.10.009

High-risk nonmuscle invasive bladder cancer

Hematol Oncol Clin North Am. 2015 Apr;29(2):227-36, viii. doi: 10.1016/j.hoc.2014.10.009. Epub 2014 Dec 19.

Authors

Anna Orsola¹, Joan Palou², Eduardo Solsona³

Affiliations

¹ Bladder Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA. Electronic address: annaorsola@gmail.com.
² Urology Department, Fundacio Puigvert, Cartagena 340-350, Barcelona 08025, Spain.
³ Urology Department, Instituto Valenciano de Oncologia, Calle del Profesor Beltrán Bàguena, 8, València 46009, Spain.

PMID: 25836931
DOI: 10.1016/j.hoc.2014.10.009

Abstract

Please also verify that the expansion of HGT1 is OK as set: The risk of progression for high-grade T1 (HGT1) cancer has been recently established at 21% using updated information on large series and a meta-analysis. These outcomes are better than those classically expected supporting the rule of thirds for HGT1. The main limitation of this subgroup is that most studies are retrospective observational studies, which, compared with randomized controlled trials, are subject to various selection biases, carrying a higher risk of uncontrolled confounding factors, with potential preferential reporting of positive findings.

Keywords: CIS; Carcinoma in situ; HGT1; High-grade T1; High-risk bladder cancer; Nonmuscle invasive bladder cancer; TUR; reTUR.

Publication types

Review

MeSH terms

Disease Management
Humans
Neoplasm Invasiveness
Neoplasm Staging
Prognosis
Risk
Urinary Bladder Neoplasms / diagnosis*
Urinary Bladder Neoplasms / mortality
Urinary Bladder Neoplasms / therapy*